title: Immunotherapy trials for type 1 diabetes: the contribution of George Eisenbarth.
abstract: Type 1 diabetes (T1D) results from the autoimmune destruction of pancreatic β-cells, and as such it should respond to immunotherapy. George Eisenbarth gave many significant contributions to this field. He has been involved at some level in most immunotherapy trials during the past three decades. He was among the pioneers who attempted immunotherapy approaches in patients with recent-onset T1D. In the early 1980s he began studying relatives of those with the disease, leading to the concept that T1D was a chronic autoimmune disease, in which islet autoimmune responses would silently destroy β-cells and cause progressive impairment of insulin secretion, years to months before a diagnosis was made. Consequently, he was one of the first to attempt immune intervention in people at high risk of T1D. Throughout his career he developed autoantibody assays and predictive models (which included metabolic testing and later genetics) to identify individuals at risk of T1D. He provided seminal intellectual contributions and critical tools for prevention trials. His focus on insulin as a critical autoantigen led to multiple prevention trials, including the Diabetes Prevention Trial-Type 1 (DPT-1), which studied both parenteral and oral insulin. In the DPT-1 Oral Insulin Trial, a cohort with higher levels of insulin autoantibodies was identified that appeared to have delayed disease progression. Type 1 Diabetes TrialNet is conducting a new trial to verify or refute this observation. Moreover, George identified and tested in the mouse small molecules that block or modulate presentation of a key insulin peptide and in turn prevent the activation of insulin-specific T-lymphocytes. Thus, we believe his greatest contribution is yet to come, as in the near future we should see this most recent work translate into clinical trials.
authors.affiliation: Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, Florida 33136, USA. jskyler@miami.ed
authors.forename: Jay S
authors.initials: JS
authors.lastname: Skyler
authors.forename: Alberto
authors.initials: A
authors.lastname: Pugliese
mesh_terms: D000069594:Abatacept; D000818:Animals; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D001323:Autoantibodies / Q000009:adverse effects* / Q000097:blood; D001324:Autoantigens / Q000276:immunology / Q000627:therapeutic use; D001327:Autoimmune Diseases / Q000188:drug therapy / Q000276:immunology; D015551:Autoimmunity / Q000276:immunology; D017252:CD3 Complex / Q000187:drug effects; D002986:Clinical Trials as Topic; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy / Q000276:immunology* / Q000517:prevention & control; D004195:Disease Models, Animal; D005260:Female; D049673:History, 20th Century; D049674:History, 21st Century; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D018796:Immunoconjugates / Q000627:therapeutic use; D007167:Immunotherapy / Q000379:methods / Q000639:trends; D007328:Insulin / Q000378:metabolism / Q000627:therapeutic use*; D007330:Insulin Antibodies / Q000276:immunology; D000078790:Insulin Secretion; D050417:Insulin-Secreting Cells / Q000276:immunology; D008297:Male; D051379:Mice; D000069283:Rituximab
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D001323:Autoantibodies; D001324:Autoantigens; D017252:CD3 Complex; D007004:Hypoglycemic Agents; D018796:Immunoconjugates; D007328:Insulin; D007330:Insulin Antibodies; D000069283:Rituximab; D000069594:Abatacept